Aileron Therapeutics, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis ...
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision onco...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ten23 health, the human-centri...
Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale glo...
Hovione Farmaciência, S.A.(“HOVIONE”) and Zerion Pharma A/S (“ZERION”) today announced that they have expanded their part...
World-leading contract research organization (CRO) Sygnature Discovery is delighted to announce the appointment of Amira Modi as its new Chief Operating ...
In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...
Thryv Therapeutics, a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, announced...
The company's intellectual property ("IP") covers the formulation and method of use of polihexanide in the treatment of acanthamoeba keratitis and fung...
To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scien...
Roche announced positive topline results from the Phase III REGENCY study, which evaluated Gazyva®/Gazyvaro® (obinutuzumab) in people with active...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...
© 2025 Biopharma Boardroom. All Rights Reserved.
